Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Guselkumab loss of exclusitivy?How to apply for vascepa's patient assistance?What is dabrafenib mesylate msn patent issue?How often should lurbinectedin's long term effects be monitored?What's the recommended schedule for lurbinectedin side effect checks?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin, a DNA damage response inhibitor, is an experimental cancer treatment developed by PharmaMar, a biopharmaceutical company. Research has shown that the compound exerts its antitumor activity by inhibiting the RNA polymerase II function, which is essential for cell growth and survival. However, like many cancer treatments, it may also cause side effects in some patients [1]. According to clinical trials, the most common side effects of lurbinectedin include myelosuppression, fatigue, nausea, and vomiting, as well as neurological symptoms such as dizziness and neuropathy [2]. Additionally, patients treated with lurbinectedin have experienced hepatotoxicity, with some developing elevated liver enzymes and even liver failure in severe cases [3]. Research has indicated that the liver injury associated with lurbinectedin is thought to result from the compound's accumulation in liver cells and its interference with cellular processes, leading to oxidative stress and inflammation [4]. It is essential for patients to report any side effects promptly to manage them effectively and maintain the treatment's efficacy. Sources: [1] https://drugs.ru/p/lu-1709 [2] DrugPatentWatch.com: Lurbinectedin [3] Nature.com - Lurbinectedin: A promising antitumor agent [4] PharmaMar: Lurbinectedin Mechanism of Action
Other Questions About Lurbinectedin :